Skip to main navigation Skip to search Skip to main content

Ceftaroline fosamil salvage therapy : an option for reduced-vancomycin-susceptible MRSA bacteraemia

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

Objectives To examine the activity of ceftaroline against reduced-vancomycin-susceptible MRSA isolates. Methods One-hundred and three MRSA blood culture isolates (predominantly ST239-MRSA-III), with varying vancomycin phenotypes, had their ceftaroline MICs determined by broth microdilution and MIC Evaluator strip (Oxoid-Thermo Fisher). Statistical analyses were performed that examined relationships with vancomycin and daptomycin MICs. Mutations in mecA were also examined. Results All 103 isolates (including 60 heteroresistant vancomycin-intermediate Staphylococcus aureus/vancomycin-intermediate S. aureus) were susceptible to ceftaroline, with one isolate displaying heteroresistance that may be related to a mecA mutation. Higher ceftaroline MICs were associated with vancomycin-susceptible S. aureus isolates. Conclusions This study highlights that ceftaroline fosamil is an option for salvage therapy based on in vitro activity.
Original languageEnglish
Pages (from-to)797-801
Number of pages5
JournalJournal of Antimicrobial Chemotherapy
Volume70
Issue number3
Publication statusPublished - 1 Mar 2015

Bibliographical note

Publisher Copyright:
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • antibiotics
  • ceftaroline
  • staphylococcus aureus infections

Fingerprint

Dive into the research topics of 'Ceftaroline fosamil salvage therapy : an option for reduced-vancomycin-susceptible MRSA bacteraemia'. Together they form a unique fingerprint.

Cite this